Literature DB >> 21233219

Strict 3' splice site sequence requirements for U2 snRNP recruitment after U2AF binding underlie a genetic defect leading to autoimmune disease.

Anna Corrionero1, Veronica A Raker, José María Izquierdo, Juan Valcárcel.   

Abstract

We report that the 3' splice site associated with the alternatively spliced exon 6 of the Fas receptor CD95 displays strict sequence requirements and that a mutation that disrupts this particular sequence arrangement leads to constitutive exon 6 skipping in a patient suffering from autoimmune lymphoproliferative syndrome (ALPS). Specifically, we find an absolute requirement for RCAG/G at the 3' splice site (where R represents purine, and / indicates the intron/exon boundary) and the balance between exon inclusion and skipping is exquisitely sensitive to single nucleotide variations in the uridine content of the upstream polypyrimidine (Py)-tract. Biochemical experiments revealed that the ALPS patient mutation reduces U2 snRNP recruitment to the 3' splice site region and that this effect cannot be explained by decreased interaction with the U2 snRNP Auxiliary Factor U2AF, whose 65- and 35-kDa subunits recognize the Py-tract and 3' splice site AG, respectively. The effect of the mutation, which generates a tandem of two consecutive AG dinucleotides at the 3' splice site, can be suppressed by increasing the distance between the AGs, mutating the natural 3' splice site AG or increasing the uridine content of the Py-tract at a position distal from the 3' splice site. The suppressive effects of these additional mutations correlate with increased recruitment of U2 snRNP but not with U2AF binding, again suggesting that the strict architecture of Fas intron 5 3' splice site region is tuned to regulate alternative exon inclusion through modulation of U2 snRNP assembly after U2AF binding.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21233219      PMCID: PMC3039140          DOI: 10.1261/rna.2444811

Source DB:  PubMed          Journal:  RNA        ISSN: 1355-8382            Impact factor:   4.942


  53 in total

1.  Cloning and domain structure of the mammalian splicing factor U2AF.

Authors:  P D Zamore; J G Patton; M R Green
Journal:  Nature       Date:  1992-02-13       Impact factor: 49.962

Review 2.  Activation-induced death of mature T cells in the regulation of immune responses.

Authors:  J H Russell
Journal:  Curr Opin Immunol       Date:  1995-06       Impact factor: 7.486

3.  The splicing factor U2AF35 mediates critical protein-protein interactions in constitutive and enhancer-dependent splicing.

Authors:  P Zuo; T Maniatis
Journal:  Genes Dev       Date:  1996-06-01       Impact factor: 11.361

4.  The splicing factor BBP interacts specifically with the pre-mRNA branchpoint sequence UACUAAC.

Authors:  J A Berglund; K Chua; N Abovich; R Reed; M Rosbash
Journal:  Cell       Date:  1997-05-30       Impact factor: 41.582

5.  Interaction of U2AF65 RS region with pre-mRNA branch point and promotion of base pairing with U2 snRNA [corrected].

Authors:  J Valcárcel; R K Gaur; R Singh; M R Green
Journal:  Science       Date:  1996-09-20       Impact factor: 47.728

6.  Mammalian U2 snRNP has a sequence-specific RNA-binding activity.

Authors:  K K Nelson; M R Green
Journal:  Genes Dev       Date:  1989-10       Impact factor: 11.361

7.  Targeting of U2AF65 to sites of active splicing in the nucleus.

Authors:  M Gama-Carvalho; R D Krauss; L Chiang; J Valcárcel; M R Green; M Carmo-Fonseca
Journal:  J Cell Biol       Date:  1997-06-02       Impact factor: 10.539

8.  Differential expression of human Fas mRNA species upon peripheral blood mononuclear cell activation.

Authors:  C Liu; J Cheng; J D Mountz
Journal:  Biochem J       Date:  1995-09-15       Impact factor: 3.857

9.  Specific interactions between proteins implicated in splice site selection and regulated alternative splicing.

Authors:  J Y Wu; T Maniatis
Journal:  Cell       Date:  1993-12-17       Impact factor: 41.582

10.  Protection from Fas-mediated apoptosis by a soluble form of the Fas molecule.

Authors:  J Cheng; T Zhou; C Liu; J P Shapiro; M J Brauer; M C Kiefer; P J Barr; J D Mountz
Journal:  Science       Date:  1994-03-25       Impact factor: 47.728

View more
  7 in total

Review 1.  Post-transcriptional coordination of immunological responses by RNA-binding proteins.

Authors:  Panagiota Kafasla; Antonis Skliris; Dimitris L Kontoyiannis
Journal:  Nat Immunol       Date:  2014-06       Impact factor: 25.606

2.  Splicing inhibition of U2AF65 leads to alternative exon skipping.

Authors:  Sunghee Cho; Heegyum Moon; Tiing Jen Loh; Ha Na Jang; Yongchao Liu; Jianhua Zhou; Takbum Ohn; Xuexiu Zheng; Haihong Shen
Journal:  Proc Natl Acad Sci U S A       Date:  2015-07-27       Impact factor: 11.205

3.  U5 snRNA Interactions With Exons Ensure Splicing Precision.

Authors:  Olga V Artemyeva-Isman; Andrew C G Porter
Journal:  Front Genet       Date:  2021-07-02       Impact factor: 4.599

4.  Isolated pseudo-RNA-recognition motifs of SR proteins can regulate splicing using a noncanonical mode of RNA recognition.

Authors:  Antoine Cléry; Rahul Sinha; Olga Anczuków; Anna Corrionero; Ahmed Moursy; Gerrit M Daubner; Juan Valcárcel; Adrian R Krainer; Frédéric H-T Allain
Journal:  Proc Natl Acad Sci U S A       Date:  2013-07-08       Impact factor: 11.205

5.  Alternative splicing of RNA triplets is often regulated and accelerates proteome evolution.

Authors:  Robert K Bradley; Jason Merkin; Nicole J Lambert; Christopher B Burge
Journal:  PLoS Biol       Date:  2012-01-03       Impact factor: 8.029

6.  Intron retention in the alternatively spliced region of RON results from weak 3' splice site recognition.

Authors:  Lindsay D Smith; Christian M Lucas; Ian C Eperon
Journal:  PLoS One       Date:  2013-10-14       Impact factor: 3.240

7.  The Activation-Induced Assembly of an RNA/Protein Interactome Centered on the Splicing Factor U2AF2 Regulates Gene Expression in Human CD4 T Cells.

Authors:  Thomas C Whisenant; Eigen R Peralta; Lauren D Aarreberg; Nina J Gao; Steven R Head; Phillip Ordoukhanian; Jamie R Williamson; Daniel R Salomon
Journal:  PLoS One       Date:  2015-12-07       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.